Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- IMAB
- Price
- 2.50
- Stock movement up
- +0.19 (4.20%)
- Company name
- I-Mab
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 384.62M
- Ent value
- 320.09M
- Price/Sales
- 52.92
- Price/Book
- 1.77
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 4.82%
- 1 year return
- 295.80%
- 3 year return
- -16.08%
- 5 year return
- -30.90%
- 10 year return
- -
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
IMAB does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 52.92 |
| Price to Book | 1.77 |
| EV to Sales | 44.05 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 81.66M |
| EPS (TTM) | -0.51 |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 7.27M |
| Gross profit (TTM) | 3.99M |
| Operating income (TTM) | -257.89M |
| Net income (TTM) | -41.46M |
| EPS (TTM) | -0.51 |
| EPS (1y forward) | -0.33 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 54.97% |
| Operating margin (TTM) | -3548.64% |
| Profit margin (TTM) | -570.53% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 79.33M |
| Net receivables | 0.00 |
| Total current assets | 188.21M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 3.69M |
| Total assets | 232.68M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 3.78M |
| Total current liabilities | 11.77M |
| Total liabilities | 14.80M |
| Shareholder's equity | 217.88M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 0.00 |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | 0.00 |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -19.03% |
| Return on Assets | -17.82% |
| Return on Invested Capital | -18.96% |
| Cash Return on Invested Capital | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.38 |
| Daily high | 4.90 |
| Daily low | 4.33 |
| Daily Volume | 1.22M |
| All-time high | 84.43 |
| 1y analyst estimate | 6.20 |
| Beta | 1.38 |
| EPS (TTM) | -0.51 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 13 Nov 2025 |
Downside potential
Loading...
Downside potential data
| IMAB | S&P500 | |
| Current price drop from All-time high | -94.42% | -1.46% |
| Highest price drop | -99.27% | -56.47% |
| Date of highest drop | 7 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -66.00% | -10.99% |
| Avg time to new high | 38 days | 12 days |
| Max time to new high | 1040 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
384.62M
Marketcap category
Small-cap
Description
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
Employees
32
Investor relations
-
SEC filings
CEO
Huaqiong Shen
Country
USA
City
Pudong
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page